Mangalam Drugs and Organics' Q2 FY 2025-26 Quarterly Results

Result Summary

• Mangalam Drugs and Organics Ltd reported a 13.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 38.1%.
• Its expenses for the quarter were down by 19.0% QoQ and 27.7% YoY.
• The net profit decreased 46.7% QoQ and decreased 373.2% YoY.
• The earnings per share (EPS) of Mangalam Drugs and Organics Ltd declined at 4.64 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Mangalam Drugs and Organics Ltd is a company operating in the pharmaceutical sector, primarily involved in the production of active pharmaceutical ingredients (APIs) and intermediates. The company has a longstanding presence in the industry, focusing on the manufacturing of key pharmaceutical compounds that are essential for the formulation of various drugs. Mangalam Drugs and Organics Ltd serves both domestic and international markets, providing products that are integral to the healthcare and pharmaceutical supply chains. While specific recent major developments are not provided, the company is known for its contribution to the pharmaceutical manufacturing landscape, catering to a range of therapeutic categories.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Mangalam Drugs and Organics Ltd reported total income of ₹49.57 crores. This represents a decline of 13.6% compared to the previous quarter (Q1FY26) where the total income was ₹57.35 crores. When compared to the same quarter in the previous fiscal year (Q2FY25), the total income decreased by 38.1% from ₹80.08 crores. This downward trend in revenue over both the quarter-over-quarter and year-over-year periods reflects notable changes in the company’s financial income streams.

Profitability

The company reported a loss before tax of ₹12.47 crores in Q2FY26, which is a slight improvement from a loss before tax of ₹13.00 crores in Q1FY26, reflecting a 4.1% change. However, compared to a profit before tax of ₹1.20 crores in Q2FY25, this marks a significant year-over-year decline of 1139.2%. The tax credit in Q2FY26 was ₹5.12 crores, contrasting with a tax expense of ₹0.80 crores in the previous quarter and a credit of ₹1.49 crores in Q2FY25. Consequently, the profit after tax in Q2FY26 was a loss of ₹7.35 crores, improving by 46.7% from a loss of ₹13.80 crores in Q1FY26. However, this reflects a substantial decline from a profit after tax of ₹2.69 crores in Q2FY25, indicating a year-over-year decrease of 373.2%.

Operating Metrics

Earnings per share (EPS) for Q2FY26 stood at a negative ₹4.64, which marks an improvement of 46.8% from negative ₹8.72 in Q1FY26. However, this is a substantial decline from an EPS of ₹1.70 in Q2FY25, amounting to a year-over-year decrease of 372.9%. The company’s total expenses in Q2FY26 were ₹57.01 crores, representing a decrease of 19.0% from ₹70.35 crores in the previous quarter. Compared to Q2FY25, there was a reduction in total expenses by 27.7% from ₹78.88 crores. This decline in expenses aligns with the reduced income, yet the company continues to operate at a loss, as indicated by the negative profitability metrics.